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Context: Borderline personality disorder is a severe and
chronic psychiatric condition, prevalent throughout health
care settings. Only limited effects of current treatments
have been documented.
Objective: To compare the effectiveness of schema-
focused therapy (SFT) and psychodynamically based
transference-focused psychotherapy (TFP) in patients with
borderline personality disorder.
Design: A multicenter, randomized, 2-group design.
Setting: Four general community mental health centers.
Participants: Eighty-eight patients with a Borderline Per-
sonality Disorder Severity Index, fourth version, score
greater than a predetermined cutoff score.
Intervention: Three years of either SFT or TFP with
sessions twice a week.
Main OutcomeMeasures: Borderline Personality Dis-
order Severity Index, fourth version, score; quality of life;
general psychopathologic dysfunction; and measures of
SFT/TFP personality concepts. Patient assessments were
made before randomization and then every 3 months for
3 years.
Results: Data on 44 SFT patients and 42 TFP patients
were available. The sociodemographic and clinical char-
acteristics of the groups were similar at baseline. Sur-
vival analyses revealed a higher dropout risk for TFP
patients than for SFT patients (P=.01). Using an intention-
to-treat approach, statistically and clinically significant
improvements were found for both treatments on all mea-
sures after 1-, 2-, and 3-year treatment periods. After 3
years of treatment, survival analyses demonstrated that
significantly more SFT patients recovered (relative
risk=2.18; P=.04) or showed reliable clinical improve-
ment (relative risk=2.33; P=.009) on the Borderline Per-
sonality Disorder Severity Index, fourth version. Robust
analysis of covariance (ANCOVA) showed that they also
improved more in general psychopathologic dysfunc-
tion and measures of SFT/TFP personality concepts
(P.001). Finally, SFT patients showed greater in-
creases in quality of life than TFP patients (robust
ANCOVAs, P=.03 and P.001).
Conclusions: Three years of SFT or TFP proved to be ef-
fective in reducing borderline personality disorder–
specific and general psychopathologic dysfunction and
measures of SFT/TFP concepts and in improving quality
of life; SFT is more effective than TFP for all measures.
Arch Gen Psychiatry. 2006;63:649-658
B ORDERLINE PERSONALITY DIS-order (BPD) is marked bychronicinstabilityinmultipleareas (ie, emotionaldysregu-lation,self-harm,impulsivity,
and identity disturbance). The prevalence
of BPD is estimated to be 1% to 2.5% in the
general population and 10% to 50% in psy-
chiatric outpatient and inpatient settings.1
Themedical andother societal costsofBPD
aresubstantial2 (alsoT.V.A.,C.D.,A.A., and
JohannisSeverens,PhD,unpublisheddata,
September 2005). Suicide risk is estimated
to be up to 10%.3 A few treatments—
outpatientdialecticalbehaviortherapy4-8and
psychoanalyticallyoriented treatments9-11—
have demonstrated some effectiveness in
randomized clinical trials of patients with
BPD, as manifested by good treatment re-
tention and reduced suicide attempts, acts
of self-harm, and hospitalizations. How-
ever, no pharmacologic or psychosocial
treatment has demonstrated efficacy for all
aspects of BPD, such as affective, identity,
and interpersonal disturbances.12
We compared the effectiveness of 2 pro-
longed outpatient treatments that aim at
achieving full recovery from BPD: schema-
focused therapy (SFT)13-15 and transfer-
ence-focused psychotherapy (TFP).16,17
Schema-focused therapy is an integrative
cognitive therapy, and TFP is a psycho-
dynamically based psychotherapy. Both
treatments intend to bring about a struc-
Author Affiliations are listed at
the end of this article.
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tural change in patients’ personality, which should be ap-
parent not only from a decrease in self-destructive be-
haviors but also from reduced pathologic personality
features, reduced general psychopathologic dysfunc-
tion, and increased quality of life. In designing this ran-
domized controlled trial, we decided to compare SFT and
TFP because (1) these treatments seemed promising af-
ter an uncontrolled pilot study and therapists’ indi-
vidual clinical experiences (now further supported by
open studies18-20), (2) earlier studies already demon-
strated that specialized psychotherapeutic approaches are
more effective than control conditions (including treat-
ment as usual and natural course),4,7-9,21 and (3) no treat-
ment as usual could control for treatment goals, inten-
sity, and session frequency.
METHODS
STUDY DESIGN
A multicenter, randomized, 2-group design was used. Ran-
domization to SFT or TFP was stratified across 4 community
mental health centers and was performed by a study-
independent person after the adaptive biased urn procedure.22
We used this procedure (1) to keep allocation at each site un-
predictable until the last patient to avoid unintentionally af-
fecting ongoing screening procedures and (2) to keep the num-
ber of patients in balance between the conditions at each site.
Each patient’s first assessment occurred after inclusion and be-
fore randomization. Then, assessments were made every 3
months for 3 years by independent research assistants.
Therapists at secondary and tertiary community mental
health institutes in the areas of the 4 participating treatment
centers referred patients based on a clinical diagnosis of BPD.
Patients were then assessed at each site (patients from The Hague
were assessed in Leiden) using the Structured Clinical Inter-
views for the DSM-IV, versions I and II.23-26 Patients were fur-
ther screened using a semistructured clinical interview, the Bor-
derline Personality Disorder Severity Index, fourth version
(BPDSI-IV) (score range, 0-90)27(also J.G.-B., Lieven Wachter,
MSc, Erik Schouten, BSc, and A.A., unpublished data, July 2005).
All the study therapists were affiliated with 1 of the 4 treat-
ment centers. Nine experienced and extensively trained thera-
pists with a master’s degree in psychology diagnosed patients
(2 therapists in Amsterdam, 4 in Leiden/The Hague, and 3 in
Maastricht). All of the interviews we used are highly reli-
able.28-30 The BPDSI-IV cutoff score of 20 also discriminates pa-
tients with BPD from patients with other personality disorders
( J.G.-B., Lieven Wachter, MSc, Erik Schouten, BSc, and A.A.,
unpublished data, July 2005), cross-checking the Structured
Clinical Interview for the DSM-IV, version 2.024,26 BPD diag-
nosis. Self-report questionnaires (the Dissociative Experi-
ences Scale31 and the Dutch Screening List for Attention Defi-
cit Hyperactivity Disorder for Adults32) were used in the
screening process, if indicated, followed by the Structured Clini-
cal Interview for DSM-IV Dissociative Disorders33,34 or an ad-
justed semistructured interview for attention-deficit/
hyperactivity disorder.35 If low intelligence or illiteracy was
suspected, the Wechsler Adult Intelligence Scale36 or the Dutch
Adult Reading Test37 was administered. A positive screening
procedure took 2 months, and this interval served as a pa-
tient’s motivational check for undergoing intensive psycho-
therapy. Signed informed consent was obtained after full ex-
planation of the procedures and of both therapies before the
first assessment and randomization. Thirteen experienced and
trained research assistants with higher vocational training in
psychology assessed patients for treatment outcome measures
(4 research assistants in Amsterdam, 5 in Leiden/The Hague,
and 4 in Maastricht). Study researchers, screeners, research as-
sistants, and SFT/TFP therapists were masked to treatment al-
location during the screening procedure and the first assess-
ment. The medical ethics committees of the participating centers
approved the study. Participants did not receive compensa-
tion for screening or assessments but were exempt from the
Dutch standard personal contribution to psychotherapy ses-
sions (then $10 per session). Participating in assessments was
obligatory to receiving therapy.
PATIENTS
Inclusion criteria were a main diagnosis of BPD, age 18 to 60
years, BPDSI-IV score greater than 20, and Dutch literacy. Gen-
eral exclusion criteria were psychotic disorders (except short,
reactive psychotic episodes), bipolar disorder, dissociative iden-
tity disorder, antisocial personality disorder, attention-deficit/
hyperactivity disorder, addiction of such severity that clinical
detoxification was indicated (after which entering treatment
was possible), psychiatric disorders secondary to medical con-
ditions, and mental retardation. These disorders were ex-
cluded because they generally need primary treatment. An ex-
ception is antisocial personality disorder because its “lie” feature
is an explicit contraindication for TFP. Comorbid Axis I and
Axis II disorders were allowed, as was medication use.
TREATMENT CONDITIONS AND THERAPISTS
Both treatments were offered in 50-minute sessions twice a week.
Treatment protocols addressed the theoretical model, treatment
frame, different phases, and use of strategies and tech-
niques.13,14,16,17 Central to SFT is the assumption of 4 schema modes
specific to BPD. Schema modes are sets of schemas expressed in
pervasive patterns of thinking, feeling, and behaving. The distin-
guished modes in BPD are detached protector, punitive parent,
abandoned/abused child, and angry/impulsive child. In addi-
tion, some presence of the healthy adult is assumed. Change is
achieved through a range of behavioral, cognitive, and experien-
tial techniques that focus on (1) the therapeutic relationship, (2)
daily life outside therapy (also through homework assign-
ments), and (3) past (traumatic) experiences. Recovery in SFT
is achieved when dysfunctional schemas no longer control or rule
the patient’s life. Central to TFP is a negotiated treatment con-
tract between patient and therapist, being the treatment frame.
Change is achieved through analyzing and interpreting the trans-
ference relationship, focusingon thehere-and-nowcontext.Promi-
nent techniques are exploration, confrontation, and interpreta-
tion. Recovery in TFP is reached when good and bad
representations of self (and of others) are integrated and when
fixed primitive internalized object relations are resolved.
Nine therapists treated 1 patient each (4 SFT and 5 TFP),
28 treated 2 patients each (17 SFT and 11 TFP), and 7 treated
3 patients each (2 SFT and 5 TFP), with no between-group dif-
ferences (P=.27). Three therapists held doctoral degrees (1 SFT
and 2 TFP), 37 held master’s degrees (19 SFT and 18 TFP),
and 4 held bachelor’s degrees with postgraduate training (3 SFT
and 1 TFP), with no between-group differences (P=.42). All
the therapists had previous therapy experience in their orien-
tation with patients with BPD (mean [SD]: SFT, 9.95 [4.98]
years ; TFP, 11.73 [6.28] years), with no between-group dif-
ferences (P=.39). There were significantly more female SFT
therapists than TFP therapists (15 vs 7; P=.04), but without
significantly contributing to treatment outcome (P=.92).
Two supervisors initially trained the therapists. Essential to
both treatments is supervision. Weekly local supervision with
(REPRINTED) ARCH GEN PSYCHIATRY/ VOL 63, JUNE 2006 WWW.ARCHGENPSYCHIATRY.COM
650
©2006 American Medical Association. All rights reserved.
 on September 10, 2008 www.archgenpsychiatry.comDownloaded from 
4 to 5 SFT or TFP therapists, a 1-day central supervision every
4 months, and a 2-day central supervision every 9 months by
Jeffrey Young, PhD (SFT), or Frank Yeomans, MD, PhD (TFP),
were provided throughout the study. Psychiatrists from differ-
ent orientations, including 2 SFT therapists and 3 TFP thera-
pists, regularly evaluated the patients taking medication at the
start and during treatment, prescribing according to good clini-
cal practice, similar to American Psychiatric Association guide-
lines. No other concurrent treatments were allowed.
TREATMENT INTEGRITY CHECK
Treatment integrity was monitored by means of supervision.
Randomly selected audiotapes of each quarter and of sessions
1 to 6 (for the TFP contract phase) for evaluation. All the rat-
ers were independent of the study and masked to treatment out-
come. One psychologist, masked to allocation, listened to 1 ran-
domly selected tape of each patient, then stated the treatment
administered. Eighty-five tapes were correctly classified; 1 SFT
tape was qualified TFP.
Thirty-three (partial) TFP contract phases were rated by
trained graduate students in psychology using the Contract Rat-
ing Scale,38 covering patient and therapist responsibilities dur-
ing and threats to treatment. Seven contract phase tapes had
extremely bad sound quality or were missing. Seventy-one rat-
ings were analyzed, and the mean intraclass correlation coef-
ficient (ICC) across 21 tapes was 0.46 (range, 0.17-0.67). The
contract setting adherence and competence had an average rat-
ing of 3.22 (range, 2.86-3.54); a predetermined rating of 3 was
considered adequate.38,39
Other trained therapists for each orientation assessed the TFP
Rating of Adherence and Competence Scale16 or the SFT Therapy
Adherence and Competence Scale for BPD.40 Both instruments
consist of visual analog scale and Likert scale items and have an
identical competence cutoff score of at least 60. Fifty-six TFP tapes
and 77 SFT tapes of the second or sixth trimester were rated (ICCs
across 21 TFP and 20 SFT tapes that were rated twice).
Adherence to TFP was expressed in time percentage of TFP
techniques, naming dyad-actors, and emergency focus. Only
an average of 7.5% of the time (median, 4%) was spent on non-
TFP techniques (ICC=0.71). Valid actor naming occurred in
18 of 56 rated sessions (=0.36), and emergency focus was well
kept (=0.91). The median competence level for different as-
pects of interventions, treatment frame modification, and emo-
tional contact was 65.6 (ICC=0.73). The median global com-
petence rating of the TFP therapists was 65 (ICC=0.70).
Adherence to SFT, as for overall appropriateness of used
methods and techniques in SFT, was excellent (median, 90.00;
ICC=0.76). No non-SFT techniques were observed. The me-
dian competence/quality level for applying SFT methods was
85.67 (ICC=0.69), and the median global competence/quality
of SFT therapist ratings was 73.00 (ICC=0.78).
ASSESSMENT
The primary outcome measure was the score on the BPDSI-IV,
aDSM-IV BPD criteria–based semistructured interview; this 70-
item index represents the current severity and frequency of the
DSM-IV BPD manifestations. The reference period is 3 months,
which is appropriate in this study, and shows excellent psy-
chometrics (Cronbach =.85; interrater reliability, 0.99; va-
lidity and sensitivity to change)27 (also J.G.-B., Lieven Wachter,
MSc, Erik Schouten, BSc, and A.A., unpublished data, July 2005).
Previous research27 (also J.G.-B., Lieven Wachter, MSc, Erik
Schouten, BSc, and A.A., unpublished data, July 2005) found
a cutoff score41 of 15 between patients with BPD and nonpa-
tient controls, with a specificity of 0.97 and a sensitivity of 1.00.
The recovery criterion was, therefore, defined as achieving a
BPDSI-IV score of less than 15 and maintaining this score un-
til the last assessment. A second criterion was reliable change,41
which reflects individual clinically significant improvement. For
the BPDSI-IV, reliable change was achieved when improve-
ment was at least 11.70 points at the last assessment.41
A secondary outcome measure was quality of life, assessed
by means of 2 widely used and psychometrically sound self-
report questionnaires: the EuroQol thermometer42 and the World
Health Organization quality of life assessment (WHOQOL).43
The vertical EuroQol thermometer rating indicates one’s ex-
perience level between best (100 points) and worst (0 points)
imaginable health status. The WHOQOL is a 100-item self-
report questionnaire, and through the domains of physical
health, psychological health, environment, personal convic-
tions, social relationships, and extent of independency, the WHO
concept of quality of life is assessed. Other secondary out-
come measures were assessed at 6-month instead of 3-month
intervals and consisted of general psychopathologic measures
and measures of SFT/TFP personality concepts, all in self-
report format and with robust psychometric properties. More
general measures included the BPD Checklist on the burden
of BPD-specific symptoms,27 the Symptom Checklist-90 for sub-
jective experience of general symptoms,44 the Rosenberg Self-
Esteem Scale,45 and the Miskimins Self-Goal(-Other) Discrep-
ancy Scale for the difference between one’s actual and desired/
ideal self-perception.46 Theory-specific instruments were the
Young Schema Questionnaire on schemas underlying Young’s
theory,47,48 the Personality Disorder Belief Questionnaire–
BPD section on BPD-specific beliefs derived from the Beck cog-
nitive theory of personality disorders,49 the Inventory of Per-
sonality Organization–borderline character pathology reflecting
the facets of psychoanalytical borderline organizational struc-
ture developed after Kernberg’s theory,50 and the Defense Style
Questionnaire (DSQ)–48 for mature, neurotic, and immature
defense mechanism use in daily life.51 Principal component
analysis of pretest secondary variables44-51 (also J.G.-B., Lieven
Wachter, MSc, Erik Schouten, BSc, and A.A., unpublished data,
July 2005) revealed 1 strong factor, on which only DSQ–
mature defenses did not load (loading, 0.15). Similar results
were found when analyzing the linear trends of these vari-
ables: 1 strong factor and loading of 0.01 for DSQ–mature de-
fenses. Highly similar results were obtained when other assess-
ment points were analyzed. After excluding DSQ–mature
defenses, the pretest factor’s eigenvalue was 7.51 (57.8% vari-
ance), with factor loadings of 0.47 to 0.93 (median, 0.78). The
linear trend factor’s eigenvalue was 8.63 (66.4%), with factor
loadings of 0.49 to 0.95 (median, 0.82). Composite scores for
pretest, last observation, and linear trends were derived by com-
puting factor scores using the regression method, and they are
labeled psycho- and personality pathology.
SAMPLE SIZE AND DATA ANALYSIS
The BPDSI-IV–based power analyses indicated that 45 pa-
tients per group are needed to detect a 22% vs 50% recovery
difference between 2 groups by means of survival analysis, with
a 2-sided significance level of 5% and a power of 80%. An in-
tention-to-treat approach was applied, using either the last ob-
servation during the 3-year treatment period or the last-
observation-carried-forward method for trend analyses. First,
treatment dropout survival analysis using Kaplan-Meier logis-
tic regression (because of time dependency) was executed. Sec-
ond, the effects of each treatment were evaluated using the
McKean Schrader Test Statistic (MSTS)52 on the medians of pre-
post changes. Then, Cox regression survival analyses on the
BPDSI-IV recovery status and reliable change status for 3 years
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after the start of treatment, with treatment group as the covar-
iate, were executed. Time independency of relative risks (RRs)
was checked. Between-group differences for outcome mea-
sures were examined using end point analyses and by analyz-
ing the slopes of linear trend scores across all assessments dur-
ing the 3 years because all linear trends on outcome measures
differed significantly from zero in both conditions (Wilcoxon
z1.97; P.05), except for DSQ–mature defenses (SFT: P=.90;
TFP: P=.50). Therefore, outcome measures assessed every 3
(or 6) months were first transformed into linear trend scores,
representing the linear change of these measures (except DSQ–
mature defenses) during the 3-year study.
Heteroscedasticity, skewness of distributions, regression out-
liers, and leverage point analyses revealed that assumptions for
parametric tests were not met. Robust analyses of covariance
were, therefore, used, with pretest as the covariate, using Wil-
cox analysis of covariance (ANCOVA) on medians.52,53 All the
tests were interpreted with a significance level of 5%. Analyses
were performed using SPSS version 11.5 for Windows (SPSS
Inc, Chicago, Ill) (survival analyses, within-group analyses, and
2 tests) and the Rplus (R Foundation for Statistical Comput-
ing, Vienna, Austria; http://www.r-project.org/) and Rallfun
(Rand R. Wilcox, Department of Psychology, University of
Southern California, Los Angeles; http:psychology.usc.edu/
faculty_homepage.php?id=43) Package, version 2.0.0, with ex-
tensions v1.v3 and v2.v3 (Wilcox ANCOVAs on medians).
RESULTS
PATIENT ACCRUAL
The study was conducted between September 1, 1999,
and April 30, 2004. Patient flow is presented in Figure1.
Of 173 patients referred to the study centers, 40 (23.1%)
declined participation (12 patients after initial contact
and 28 after having 1 or more appointments in the screen-
ing procedure). Another 45 patients (26.0%) were not
eligible for participation: 2 could not commit them-
selves to assessments every 3 months, 24 did not meet
the inclusion criteria (14 had no BPD diagnosis, 1 had
an anorexia nervosa diagnosis that became life-
threatening during the screening procedure and re-
quired immediate longer-term hospitalization, 1 was 17
years old, and 8 had BPDSI-IV scores20), and 19 met
the exclusion criteria (6 had bipolar disorder, 1 had psy-
chotic disorder, 1 had valium addiction and refused de-
toxification, 2 had dissociative identity disorder, 7 had
antisocial personality disorder, and 2 had attention-
deficit/hyperactivity disorder). Eighty-eight patients
(50.9%) participated in the study. Primary and second-
ary outcome variables and sociodemographic character-
istics did not differ significantly among treatment cen-
ters. One SFT patient and 1 TFP patient were excluded
from the analyses; the SFT patient’s poor eyesight made
assessments unreliable, and the TFP patient became un-
traceable after randomization.
Six (13.6%) of 44 SFT patients and 2 (4.8%) of 42 TFP
patients successfully terminated treatment within 3 years,
only coded as such when patient and therapist agreed on
termination. No treatment was terminated because the
therapist thought the patient was ready to end or owing
Patients Screened for Eligibility173
Randomized88
Patients Allocated to SFT45 Patients Allocated to TFP43
Patients Excluded85
Declined Participation40
Did Not Meet Inclusion Criteria24
Met Exclusion Criteria19
Had Insufficient Availability2
Reasons
Lost to Therapy and Assessments12
Between 6 and 9 mo2
Between 9 and 12 mo1
Between 12 and 15 mo2
Between 18 and 21 mo3
Between 27 and 30 mo2
Between 30 and 33 mo2
Had No Faith in SFT or Therapist6
Because of SFT Limit Setting2
For Psychotic Decompensation2
(1 Patient Was Falsely Included,
Earlier Psychoses Overseen)
For Deteriorating Somatic
Condition
1
Considered Herself Recovered1
Reasons
Lost to Therapy and Assessments22
Between 0 and 3 mo8
Between 3 and 6 mo3
Between 6 and 9 mo1
Between 9 and 12 mo4
Between 18 and 21 mo4
Between 27 and 30 mo1
Between 24 and 27 mo1
Had No Faith in TFP or Therapist10
Considered Themselves
Recovered
4
For TFP Contract Breech3
For No TFP Contract Reached
at Start
2
Was Untraceable, Never Started1
Unknown1
Had a Contraindication at
Therapist Evaluation
1
Completed SFT33
Finished SFT Within 24 mo2
Finished SFT Within 36 mo4
Are Still in Treatment27
Completed TFP21
Finished TFP Within 24 mo1
Finished TFP Within 36 mo1
Are Still in Treatment19
Included in Analyses (1 Patient
Excluded Because Untraceable
After Randomization; Never Met
or Spoke to Therapist)
42Included in Analyses (1 Patient
Excluded Owing to Unreliable
Assessments Due to Increased
Blindness)
44
Figure 1. Patient flow in the randomized controlled trial. SFT indicates
schema-focused therapy; TFP, transference-focused psychotherapy.
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Figure 2. Proportion of patients undergoing transference-focused
psychotherapy (TFP) and schema-focused therapy (SFT).
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to refusal of assessments. Twenty-seven SFT patients
(61.4%) and 19 TFP patients (45.2%) were still in treat-
ment after 3 years. So-called completer SFT patients (ter-
minated treatment or still in treatment) had significant
fewer therapy sessions than completer TFP patients (me-
dian: 189.5 vs 231.0; MSTS=3.12; P=.002). When pa-
tients dropped out of treatment can be read from Figure 1
and Figure 2. No patient committed suicide. Survival
analyses on the attrition rates show that TFP patients have
a significantly larger risk of dropout than SFT patients
(Kaplan-Meier method; log-rank statistic=6.15; P=.01)
(Figure 2). The SFT dropout patients had significantly
more sessions than TFP dropout patients (median: 98 vs
34; MSTS=3.53; P.001).
TREATMENT GROUPS AT BASELINE
Table 1 gives an overview of patients’ characteristics in
both conditions at baseline. Age, sex, educational level,
employment status, and psychotropic medication use did
not differ significantly between treatment groups. Pa-
tients were mainly women in their 20s and 30s with
average educational levels. The treatment groups had simi-
lar levels of BPD abnormality, quality of life, and psy-
cho- and personality pathology. Numbers of comorbid
Axis I and Axis II disorders were equally distributed. A
recent history of automutilating was significantly differ-
ent between groups but had no effect on BPDSI-IV treat-
ment outcome (P=.22).
TREATMENT OUTCOMES
Results of the primary and secondary outcome mea-
sures are given in Table 2 and Figure 3. Significant
effects after 3 years of SFT or TFP emerged for patients’
reduction of BPDSI scores (SFT: MSTS=−9.81, P.001,
Cohen d=2.96; TFP: MSTS=−5.99, P.001, d=1.85),
improvement in quality of life (EuroQol thermometer
score: SFT:MSTS = 6.09, P = .001, d = 1.84; TFP:
MSTS=2.06, P=.044, d=0.64; WHOQOL total score:
SFT:MSTS=4.86, P.001, d=1.46; TFP:MSTS=3.73,
P.001, d=1.16), and reduction in psycho- and person-
ality pathology (SFT: MSTS=−6.73, P.001, d=2.02;
TFP: MSTS=−2.75, P.006, d=0.84). Both SFT and
TFP patients improved significantly on all DSM-IV BPD
criteria (P.001 on all the BPDSI-IV subscales)
(Figure 4). All effects were already apparent after
1 year.
Table 1. Sociodemographic and Clinical Characteristics of 86 Study Participantsa
Schema-Focused
Therapy Group
(n = 44)
Transference-Focused
Psychotherapy Group
(n = 42)
P
Value
Age, mean (SD), y 31.70 (8.9) 29.45 (6.5) .15b
Women 40 (90.9) 40 (95.2) .43b
Education
Graduate/professional 6 (13.6) 4 (9.5)
College graduate 3 (6.8) 7 (16.7)
Some college 17 (38.6) 14 (33.3) .22b
High school graduate 5 (11.4) 10 (23.8)
Grades 7-11 13 (29.6) 7 (16.7)
Employment status
Housewife 8 (18.2) 5 (11.9)
Student 3 (6.8) 6 (14.3)
Employed 9 (20.5) 8 (19.0) .89b
Disability 17 (38.6) 17 (40.5)
Welfare 7 (15.9) 6 (14.3)
Psychotropic medication use at baseline 34 (77.3) 30 (71.4) .87b
Recent suicide planning, steps, or attemptsc 17 (38.6) 32 (76.2) .007d
Recent nonsuicidal self-injurye 21 (47.7) 24 (57.1) .09d
Meeting DSM-IV BPD criterion 5 31 (70.5) 33 (78.6) .39b
Childhood sexual abusef 31 (70.5) 26 (61.9) .40b
Childhood physical abusef 40 (90.9) 37 (88.1) .67b
Childhood emotional abuse or neglectf 42 (95.5) 37 (88.1) .21b
No. of Axis I diagnoses, mean (SE) [95% CI] 2.95 (0.23) [2.49-3.42] 2.40 (0.25) [1.89-2.92] .11g
No. of Axis II diagnoses (BPD included), mean (SE) [95% CI] 2.14 (0.18) [1.78-2.49] 2.05 (0.18) [1.68-2.42] .73g
No. of SCID II BPD criteria, mean (SE) [95% CI] 6.70 (0.16) [6.38-7.03] 7.12 (0.19) [6.72-7.52] .23g
No. of treatment modalities before baseline, mean (SE) [95% CI]h 3.00 (0.19) [2.61-3.39] 2.79 (0.20) [2.38-3.20] .45g
Abbreviations: BPD, borderline personality disorder; BPDSI-IV, Borderline Personality Disorder Severity Index, fourth version; CI, confidence interval;
SCID II PD, Structured Clinical Interview for DSM-IV Axis II Personality Disorders.
aData are given as number (percentage) except where otherwise indicated.
bBased on the Pearson 2 test.
cAccording to BPDSI-IV items 5.1 to 5.8 in the previous 3 months.
dBased on the Mann-Whitney test.
eAccording to BPDSI-IV items 5.11 to 5.13 in the previous 3 months.
fAssessed using the structured childhood trauma interview.
gBased on analysis of variance.
hRange, 0 to 6; individual treatment, group treatment, family/couples therapy, daily medication, clinical treatment, and otherwise.
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Survival analysis on the BPDSI-IV recovery criterion with
treatment group and baseline BPDSI-IV as predictors (co-
variates) showed a significant effect in favor of SFT (Wald
statistic=3.88; P=.049; RR=2.15; 95% confidence inter-
val [CI], 1.00-4.59); baseline BPDSI-IV was not signifi-
cant (P=.38) (Figure 4). Without baseline BPDSI-IV, the
group effect was comparable (Wald statistic=4.04; P=.04;
RR=2.18; 95% CI, 1.02-4.66). Differential dropout can
only partly explain the difference between treatments be-
cause survival analysis with dropout status as an addi-
tional covariate was not significant for dropout, and the
group effect became nonsignificant, although still in the
same direction (group Wald statistic = 2.67; P= .10;
RR=1.91; 95% CI, 0.88-4.14 and dropout Wald=1.90;
P=.17; RR=1.84; 95% CI, 0.77-4.35). The group effect
persisted when the analysis was adjusted for the use of
psychotropic medication as a time-dependent covariate
(13 assessments; Wald statistic=4.42; P=.04; RR=2.26;
95% CI, 1.06-4.85). Baseline BPDSI-IV was not signifi-
cant (P=.33). Psychotropic medication use had a signifi-
cant negative effect on recovery (Wald statistic=6.21;
P=.01; RR=0.38; 95% CI, 0.18-0.81): 55% of patients who
did not use medication at the start recovered compared
with 28% of those using medication. The treatment
groupmedication interaction was not significant. Pa-
tient use of psychotropic medications across time is shown
in Figure 5. In addition, 1 TFP patient started taking a
Table 2. Primary and Secondary Outcome Measures in 86 Study Participantsa
Schema-Focused Group
(n = 44)
Transference-Focused Group
(n = 42)
P
Value
Recovery criterion 15, yes, No. (%) 20 (45.5) 10 (23.8) .04b
Reliable change, yes, No. (%) 29 (65.9) 18 (42.9) .03b
BPDSI-IV total score (range, 0-90)c
Baseline 33.53 (1.23) [31.12 to 35.94] 34.37 (1.23) [31.96 to 36.78]
12-mo treatment 22.18 (1.67) [18.91 to 25.45] 25.13 (1.76) [21.68 to 28.58] .01d,e
24-mo treatment 17.77 (1.21) [12.32 to 20.14] 23.38 (1.79) [19.87 to 26.89]
36-mo treatment 16.24 (1.51) [13.28 to 19.20] 21.87 (1.71) [17.95 to 25.79] .005d,f
EuroQol thermometer score (range, 0-100)f
Baseline 50 (3.29) [43.55 to 56.45] 55 (2.72) [49.67 to 60.33]
12-mo treatment 56 (2.52) [51.06 to 60.94] 64 (4.85) [54.49 to 73.51] .001d,e
24-mo treatment 65 (3.49) [58.16 to 71.84] 69 (4.85) [59.49 to 78.51]
36-mo treatment 64.5 (4.66) [55.37 to 73.63] 67.5 (2.91) [61.80 to 73.20] .70d,f
WHOQOL total score (range, 4-20)g
Baseline 10.33 (0.19) [9.96 to 10.70] 10.42 (0.09) [10.24 to 10.60]
12-mo treatment 11.17 (0.26) [10.66 to 11.68] 11.17 (0.19) [10.80 to 11.54] .03d,e
24-mo treatment 11.42 (0.36) [10.71 to 12.13] 11.23 (0.26) [10.72 to 11.74]
36-mo treatment 11.59 (0.29) [11.02 to 12.16] 11.09 (0.19) [10.72 to 11.46] .16d,f
Psycho- and personality factor scoreh
Baseline 0.36 (0.06) [0.24 to 0.48] 0.64 (0.13) [0.15 to 0.89]
12-mo treatment −0.14 (0.18) [−0.49 to 0.21] 0.22 (0.13) [−0.03 to 0.47] .001d,e
24-mo treatment −0.39 (0.16) [−0.70 to −0.08] −0.02 (0.15) [−0.31 to 0.27]
36-mo treatment −0.56 (0.12) [−0.80 to −0.32] 0.13 (0.18) [−0.22 to 0.48] .007d,f
Abbreviations: ANCOVA, analysis of covariance; BPDSI-IV, Borderline Personality Disorder Severity Index, fourth version; CI, confidence interval;
WHOQOL, World Health Organization quality of life assessment.
aData are given as median (SE) [95% CI] except where otherwise indicated. Yearly assessments instead of assessments every 3 months are depicted to save space.
bBased on the Pearson 2 test.
cHigher scores indicate more severe borderline personality disorder abnormalities.
dBased on Wilcox ANCOVA: robust ANCOVA39,40 based on Wilcox Rallfun package (Rand R. Wilcox, Department of Psychology, University of Southern California,
Los Angeles; www-rfc.usc.edu/~rwilcox/).
eLinear trend Wilcox ANCOVA on medians on 13 assessments (psycho- and personality pathology, 7 assessments).
fEnd point Wilcox ANCOVA on medians.
gHigher scores indicate higher levels of quality of life.
hHigher scores indicate more psycho- and personality pathology.
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Figure 3. Median primary and secondary outcome measure scores.
A, Borderline Personality Disorder Severity Index, fourth version (BPDSI-IV)
total scores (range, 0-90). B, World Health Organization quality of life
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factor scores. SFT indicates schema-focused therapy; TFP, transference-
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mood stabilizer 3 months after the start of treatment and
continued throughout the study.
Survival analysis on reliable change status and base-
line BPDSI-IV again showed an SFT effect (Figure 4)
(Wald statistic=6.90; P=.009; RR=2.33; 95% CI, 1.24-
4.37). As expected for the BPDSI-IV–based reliable change
criterion, baseline BPDSI-IV had a significant effect (Wald
statistic=15.01; P.001; RR=1.07; 95% CI, 1.03-1.10).
The SFT effect remained after including time-
dependent psychotropic medication use (SFT Wald sta-
tistic=7.40; P=.007; RR=2.38; 95% CI, 1.27-4.43; medi-
cation Wald statistic=8.54; P=.003; RR=0.40; 95% CI,
0.22-0.74). TimeRR interactions were not significant
(recovery, P=.13; reliable change, P=.20).
Results of the Wilcox ANCOVA on BPDSI-IV medi-
ans of the last observation again proved that SFT is more
effective than TFP (MSTS=2.83; P=.005; d=0.62). Sub-
sequent linear trend analysis using Wilcox ANCOVA on
the BPDSI-IV of all 13 assessments demonstrated a simi-
lar group effect in favor of SFT (MSTS=2.66; P=.01;
d=0.58). Wilcox robust ANCOVA tests at the last ob-
servation of all median BPDSI-IV subscale scores re-
vealed that the SFT group improved significantly more
than the TFP group with respect to abandonment fears
(P=.04), relationships (P=.03), identity disturbance
(P=.02), impulsivity (P=.03), (para)suicidal behavior
(P=.048), and dissociative and paranoid ideation (P=.02)
(Figure 6). No significant group differences were found
for the other subscales, although on anger a trend in fa-
vor of SFT was observed (P=.06).
The Wilcox ANCOVA on EuroQol thermometer 3-year
treatment medians did not show a group effect. How-
ever, the linear trend analysis using Wilcox ANCOVA on
the EuroQol thermometer medians across 3 years re-
vealed a significantly sharper increase in ratings for the
SFT group than for the TFP group (MSTS=2.16; P=.03;
d=0.46). A small crossing effect was observed on the
WHOQOL: SFT patients had slightly lower total scores
than TFP patients at baseline and slightly higher total
scores after 3 years of treatment. No statistically signifi-
cant group effect emerged when the last observation me-
dians were compared using Wilcox ANCOVA, and SFT
had a stronger increase than TFP when the linear trend
across all WHOQOL assessments was analyzed using Wil-
cox ANCOVA (P.001).
Wilcox ANCOVA on psycho- and personality pathol-
ogy factor scores of last observation medians showed a
significantly larger effect for SFT than for TFP
(MSTS=2.68; P=.007; d=0.58). Linear trend analysis on
the psycho- and personality pathology factor scores across
3 years using Wilcox ANCOVA showed a significantly
steeper decline for the SFT group than for the TFP group
(MSTS=3.30; P.001; d=0.72) (Figure 3).
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COMMENT
Three years of SFT or TFP proved to bring about a sig-
nificant change in patients’ personality, shown by
reductions in all BPD symptoms and general psycho-
pathologic dysfunction, increases in quality of life, and
changes in associated personality features. Using
intention-to-treat analysis with adjustments for base-
line assessments, SFT and TFP effectiveness became
apparent at 12 months of treatment and was further
extended at 3 years of treatment. Schema-focused
therapy was superior to TFP with respect to reduction
in BPD manifestations, general psychopathologic dys-
function, and change in SFT/TFP personality con-
cepts. All in all, it seems that changes in manifest
(BPD) psychopathologic dysfunction go hand in hand
with changes in pathologic personality features. An
explanation may be that both treatments address the
level of personality, not merely the “surface” symptom
level. Schema-focused therapy was not consistently
dominant over TFP with respect to patients’ improved
quality of life, as trend and end point analyses yielded
different results.
Schema-focused therapy had a significantly lower at-
trition rate than TFP. However, both treatments dem-
onstrate that patients with BPD can be motivated for and
continue prolonged outpatient treatment. To our knowl-
edge, this is the first 3-year controlled treatment effec-
tiveness study for BPD. An additional 1-year follow-up
after the initial 3-year treatment has recently been com-
pleted. The cost-effectiveness of SFT and TFP will then
be determined.
Caution is recommended when comparing the cur-
rent findings with study results4-11 on outpatient dialecti-
cal behavior therapy (DBT) and psychoanalytically ori-
ented mentalization-based treatment (MBT). Most essential
is a different primary aim in DBT and MBT, namely, to re-
duce the self-destructive psychopathologic dysfunction of
BPD and not its overall personality change. Comparisons
are further hampered by differences in treatment setting
(outpatient vs partial hospitalization in MBT), time in-
vestment/intensity for the patient (eg, 4 hours weekly
in MBT, at least 3 to 31⁄2 in DBT, and 2 in SFT and TFP),
number of therapists involved (MBTDBTSFT/TFP), use
of (severity) outcome measures, and studied treatment du-
ration (1 year for DBT, 11⁄2 years for MBT, and 3 years for
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SFT/TFP). Still, it remains that the present study estab-
lished effectiveness for all aspects of BPD pathology and,
moreover, quality of life with large treatment effect sizes.
Regarding attrition rates and reduction of (para)
suicidality (BPDSI-IV subscales impulsivity and parasui-
cidality), SFT holds up well compared with other BPD treat-
ments studies.4-9 It can be argued that DBT and MBT are
possibly most optimal for a subgroup of patients with BPD
who have prominent parasuicidal abnormalities, whereas
SFT and TFP are meaningful for the wide range of pa-
tients with BPD. The 1-year attrition rate of the present
TFP group seems to be similar to that in an uncontrolled
TFP study by Clarkin et al18 (the difference was not sig-
nificant; 21,60=0.33; P=.57), although comparing is prob-
lematic because patients in the uncontrolled TFP study
knew beforehand what therapy they would receive and that
the free study treatment period was limited to 1 year. Re-
garding (para)suicidal behavior (BPDSI-IV subscale), our
TFP patients’ improvement seems to be larger than that
in the uncontrolled TFP study (1-year d: Clarkin et al TFP,
0.15-0.46; present study TFP, 0.67). Compared with 1 year
of cognitive therapy,54,55 our data indicate that SFT and TFP
seem to yield better results with respect to a study’s main
outcome measures (1-year d: SFT, 0.43-1.03; TFP, 0.09-
0.99; and cognitive therapy, 0.22-0.55).18,54,55 A single case
series of 18 to 36 months of SFT with large effect sizes (1.8-
2.9) further support the potential of SFT in treating BPD.20
Psychotropic medication use was related to poorer out-
come (but unrelated to BPD severity at baseline). Whether
more difficult-to-treat patients are generally taking medi-
cation, whether medication counteracts psycho-
therapy,56 or whether other factors are involved remains
unclear.
Despite that 30 patients had reached the BPDSI-IV re-
covery criterion, many were still in treatment after 3 years.
First, patient and therapist were masked to assessment
results to avoid unintentionally affecting study partici-
pants. Second, changing BPD symptoms is one thing, but
installing safe attachment, functional conscience, and
functional and positive self- and other views is another
thing. For example, self-mutilation or relation crises may
have stopped, but this does not mean that a patient’s self-
esteem has risen.
A limitation of this study is that most research
assistants learned their patients’ treatment allocation
as the study progressed, as patients talked about their
treatment and therapists. However, the results of sec-
ondary computer-assessed self-report measures (in an
individual, private setting) concurred with the
observer-rated (interview) findings, making it unlikely
that results can be contributed to knowledge of treat-
ment allocation. In addition, study psychiatrists were
not per se masked to patient treatment allocation. A
third limitation is the absence of a natural-course con-
trol group.
Recently, Zanarini and colleagues57 found that symp-
tomatic improvement in BPD phenomenology is com-
mon and stable among patients with BPD during a 6-year
natural-course follow-up. A difficulty in interpreting the
findings of Zanarini and colleagues is whether improve-
ment is the natural course in BPD or the result of re-
ceived treatments or other factors. Note that previous stud-
ies found specialized psychotherapy to be superior to
natural-course or control treatments.4,7-9,21 Moreover, the
differences in outcome between SFT and TFP are due to
treatment, otherwise results should have been the same
after 3 years of treatment.
In conclusion, this study contributes to a positive
treatment perspective for BPD by lending support to
SFT as a valid evidence-based practice. However,
straightforward recommendations for clinical practice
cannot and should not be made on the basis of only 1
effectiveness study. More research is needed to repli-
cate and subsequently solidify current findings, for
example, comparisons of SFT/TFP with other specific
BPD treatments, treatment as usual, and the natural
course. Furthermore, possible adjustments within the
treatment frames could be explored, as health care
efficiency is the target of many countries’ policies and
economics. Hypothesized effective ingredients of SFT
for patients with BPD may be (1) the model’s transpar-
ency, (2) the therapist’s “reparenting” attitude on the
attachment issues of patients with BPD, (3) the many
hands-on techniques/strategies that offer a patient
structure and control, and (4) the opportunity to con-
tact the SFT therapist (within limits) between ses-
sions. Future research needs to identify factors that
facilitate optimal treatment indication.
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Correction
Errors in Table and Figure. In the Original Article by Giesen-Bloo et al titled “Outpatient Psychotherapy for Borderline
Personality Disorder: Randomized Trial of Schema-Focused Therapy vs Transference-Focused Psychotherapy,” pub-
lished in the June issue of the ARCHIVES (2006;63:649-658), there were several errors in Table 1. The table is reprinted
correctly as follows. Furthermore, neither recent suicide planning, steps, or attempts nor recent nonsuicidal self-injury
were significantly related to recovery from borderline personality disorder or changed the difference between schema-
focused therapy and transference-focused psychotherapy when these variables were entered alone or in combination in
the survival analyses. In all analyses, schema-focused therapy remained superior to transference-focused psychotherapy.
Treatment group by suicidal or self-injury manifestation interaction was not significant. In addition, the x-axis label in
Figure 3A, B, and C should have been “Assessment” rather than “Month.” The ARCHIVES regrets these errors.
Table 1. Sociodemographic and Clinical Characteristics of 86 Study Participantsa
Schema-Focused
Therapy Group
(n = 44)
Transference-Focused
Psychotherapy Group
(n = 42)
P
Value
Age, mean (SD), y 31.70 (8.89) 29.45 (6.47) .15b
Women 40 (90.9) 40 (95.2) .43b
Education
Graduate/professional 6 (13.6) 4 (9.5)
.22b
College graduate 3 (6.8) 7 (16.7)
Some college 17 (38.6) 14 (33.3)
High school graduate 5 (11.4) 10 (23.8)
Grades 7-11 13 (29.6) 7 (16.7)
Employment status
Housewife 8 (18.2) 5 (11.9)
.89b
Student 3 (6.8) 6 (14.3)
Employed 9 (20.5) 8 (19.0)
Disability 17 (38.6) 17 (40.5)
Welfare 7 (15.9) 6 (14.3)
Psychotropic medication use at baseline 34 (77.3) 30 (71.4) .87b
Recent suicide planning, steps, or attemptsc 17 (38.6) 24 (57.1) .09b
Recent nonsuicidal self-injuryd 21 (47.7) 32 (76.2) .007b
Meeting DSM-IV BPD criterion 5 31 (70.5) 33 (78.6) .39b
Childhood sexual abusee 31 (70.5) 26 (61.9) .40b
Childhood physical abusee 40 (90.9) 37 (88.1) .67b
Childhood emotional abuse or neglecte 42 (95.5) 37 (88.1) .21b
No. of Axis I diagnoses, mean (SE) [95% CI] 2.95 (0.23) [2.49-3.42] 2.40 (0.25) [1.89-2.92] .11f
No. of Axis II diagnoses (BPD included), mean (SE) [95% CI] 2.14 (0.18) [1.78-2.49] 2.05 (0.18) [1.68-2.42] .73f
No. of SCID II BPD criteria, mean (SE) [95% CI] 6.70 (0.16) [6.38-7.03] 7.12 (0.19) [6.72-7.52] .23f
No. of treatment modalities before baseline, mean (SE) [95% CI]g 3.00 (0.19) [2.61-3.39] 2.79 (0.20) [2.38-3.20] .45f
Abbreviations: BPD, borderline personality disorder; BPDSI-IV, Borderline Personality Disorder Severity Index, fourth version; CI, confidence
interval; SCID II PD, Structured Clinical Interview for DSM-IV Axis II Personality Disorders.
aData are given as number (percentage) except where otherwise indicated.
bBased on the Pearson 2 test.
cAccording to BPDSI-IV items 5.11 to 5.13 in the previous 3 mo.
dAccording to BPDSI-IV items 5.1 to 5.8 in the previous 3 mo.
eAssessed using the structured childhood trauma interview.
fBased on analysis of variance.
gRange, 0 to 6; individual treatment, group treatment, family/couples therapy, daily medication, clinical treatment, and otherwise.
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